SCHEMBL437476

SCHEMBL437476

FC(F)(F)c1ccc2nc(Cl)c(Cl)nc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.61
BACE1 P56817 1/20 0.47
EPHX2 P34913 1/20 0.44
SCN4A P35499 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
DHFR P00374 4/20 0.42
PKM P14618 2/20 0.41
NPBWR1 P48145 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
THRB P10828 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
STAT6 P42226 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12502830 0.87 KDM4E (0.53) KDM4EBACE1MEN1KMT2ADHFR
SCHEMBL12502947 0.87 KDM4E (0.53) KDM4EBACE1MEN1KMT2ADHFR
SCHEMBL28796011 0.83 KDM4E (0.49) KDM4EBACE1EPHX2SCN4AMEN1
SCHEMBL7350034 0.83 KDM4E (0.49) KDM4EBACE1EPHX2SCN4AMEN1
SCHEMBL7348872 0.83 KDM4E (0.49) KDM4EBACE1EPHX2SCN4AMEN1
SCHEMBL12355859 0.83 KDM4E (0.66) KDM4EBACE1EPHX2SCN4AMEN1
SCHEMBL12355858 0.83 KDM4E (0.66) KDM4EBACE1EPHX2SCN4AMEN1
SCHEMBL27877188 0.82 KDM4E (0.51) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL11809163 0.81 KDM4E (0.63) KDM4EBACE1EPHX2SCN4AMEN1
SCHEMBL13641613 0.81 KDM4E (0.63) KDM4EBACE1EPHX2SCN4AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0234173-B1 PHENOXY-SUBSTITUTED BETA-CARBOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1993-06-16 EP claimed
WO-2025021868-A1 TRAF2 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2025-01-30 WO disclosed
US-9936700-B2 Substituted quinoxaline derivatives as pest control agent BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-04-10 US disclosed
EP-3060557-A1 SUBSTITUTED QUINOXALINE DERIVATIVES AS PEST CONTROL AGENT Bayer CropScience Aktiengesellschaft (DE) 2016-08-31 EP disclosed
CN-105873914-A Substituted quinoxaline derivatives as pest control agents 拜耳作物科学股份公司 2016-08-17 CN disclosed
US-20160227779-A1 SUBSTITUTED QUINOXALINE DERIVATIVES AS PEST CONTROL AGENT BRETSCHNEIDER, NIKLAS TIM (DE) 2016-08-11 US disclosed
WO-2015059088-A1 SUBSTITUTED QUINOXALINE DERIVATIVES AS PEST CONTROL AGENT BAYER CROPSCIENCE AG (DE) 2015-04-30 WO disclosed
EP-2509983-B1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY MERCK SHARP & DOHME (US) 2014-09-17 EP disclosed
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
EP-0784083-A2 Composition and use of substituted 1,3-dithiolo-and 1,4-dithiinoquinoxalines as an antimicrobial THE DOW CHEMICAL COMPANY (US) 1997-07-16 EP disclosed
US-5504085-A TREATING ISCHEMIA, ANOXIA, HYPOGLYCEMIA AND HEAD, SPINAL CORD TRAUMA NOVO NORDISK A/S (DK) 1996-04-02 US disclosed
EP-0633885-A1 TRIAZOLOQUINOXALIN-1,4-DIONES AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1995-01-18 EP disclosed
EP-0573635-A1 COMPOSITION AND USE OF SUBSTITUTED 1,3-DITHIOLO- AND 1,4-DITHIINOQUINOXALINES AS AN ANTIMICROBIAL THE DOW CHEMICAL COMPANY (US) 1993-12-15 EP disclosed
WO-1993013106-A1 COMPOSITION AND USE OF SUBSTITUTED 1,3-DITHIOLO- AND 1,4-DITHIINOQUINOXALINES AS AN ANTIMICROBIAL THE DOW CHEMICAL COMPANY (US) 1993-07-08 WO disclosed
EP-0234173-B1 PHENOXY-SUBSTITUTED BETA-CARBOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1993-06-16 EP disclosed
US-5200409-A For preventing growth of marine organisms on an exposed surface THE DOW CHEMICAL COMPANY (US) 1993-04-06 US disclosed
WO-1993006103-A1 TRIAZOLOQUINOXALIN-1,4-DIONES AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1993-04-01 WO disclosed
EP-0234173-A2 Phenoxy-substituted beta-carboline derivatives, their preparation and their use as medicaments SCHERING AKTIENGESELLSCHAFT (DE) 1987-09-02 EP disclosed
US-4200748-A ANXIOLYTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1980-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160227779-A1 SUBSTITUTED QUINOXALINE DERIVATIVES AS PEST CONTROL AGENT CHRM1, CHRM2, ACHE KDM4E 1076/4885BACE1 4321/4885EPHX2 230/4885
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 KDM4E 1897/4885BACE1 2002/4885EPHX2 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.